<p>Spyre Therapeutics, Inc.（纳斯达克代码：SYRE - 获取免费报告）在目前覆盖该公司的七家券商中获得了 “买入” 的共识评级，Marketbeat 报道称。七位股票研究分析师对该股票给予了买入推荐。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 54.83 美元。</p>
<p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
<p>几家券商最近对 SYRE 进行了评估。罗伯特·W·贝尔德在 11 月 13 日的研究报告中将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并给予该公司 “跑赢大盘” 的评级。古根海姆在 10 月 25 日的研究报告中将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 1 月 13 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Spyre Therapeutics 的股票设定了 65.00 美元的目标价。</p>
<p><strong>阅读我们关于 SYRE 的最新报告</strong></p>
<h2>机构投资者对 Spyre Therapeutics 的看法</h2>
<p>一些机构投资者最近调整了对 SYRE 的持股。亨廷顿国家银行在第四季度购买了 Spyre Therapeutics 的新头寸，价值约 34,000 美元。未来资产全球投资有限公司在第四季度收购了 Spyre Therapeutics 的新股份，价值约 46,000 美元。Quest Partners LLC 在第三季度将其在 Spyre Therapeutics 的股份增加了 271.2%。Quest Partners LLC 现在拥有 5,654 股该公司的股票，价值 166,000 美元，在此期间又购买了 4,131 股。KLP Kapitalforvaltning AS 在第四季度购买了 Spyre Therapeutics 的新股份，价值约 182,000 美元。最后，Intech Investment Management LLC 在第三季度收购了 Spyre Therapeutics 的新股份，价值约 246,000 美元。机构投资者持有该公司 80.39% 的股票。</p>
<h2>Spyre Therapeutics 股价上涨 1.1%</h2>
<p>SYRE 股票周一开盘价为 22.92 美元。Spyre Therapeutics 的 52 周低点为 20.07 美元，52 周高点为 47.97 美元。该公司的市值为 11.8 亿美元，市盈率为-3.07，贝塔值为 2.85。该公司的 50 日简单移动平均线为 23.11 美元，200 日简单移动平均线为 27.13 美元。</p>
<h2>关于 Spyre Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Spyre Therapeutics, Inc.是一家处于临床前阶段的生物技术公司，专注于为患有炎症性肠病（IBD）的患者开发治疗药物。它开发的 SPY001 是一种人源单克隆免疫球蛋白 G1 抗体，旨在选择性地结合 a4ß7 整合素，正在开发用于治疗 IBD（溃疡性结肠炎和克罗恩病）。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Spyre Therapeutics</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>Symbotic 股价下跌 37%——是时候勇敢还是谨慎？</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>高收益医疗：3 只股息强劲的股票</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>超越折扣区：3 只领先的折扣零售股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元吗？</h2>
<p>在你进行下一笔交易之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
<p>我们的团队已确定五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而且没有任何大牌股票在名单上。</p>
<p>他们认为这五只股票是投资者现在购买的五家最佳公司……</p>
<p>查看这五只股票</p>
<h2>你现在应该投资 1,000 美元在 Spyre Therapeutics 吗？</h2>
<p>在你考虑 Spyre Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Spyre Therapeutics 并不在名单上。</p>
<p>虽然 Spyre Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SYRE

<p>Spyre Therapeutics, Inc.（纳斯达克代码：SYRE）获得了七家券商的一致 “买入” 评级。12 个月的平均目标价为 54.83 美元，最近 Robert W. Baird 和 Guggenheim 将其目标价上调至 65.00 美元。机构投资者持有该股票的 80.39%，开盘价为 22.92 美元，52 周价格区间为 20.07 美元至 47.97 美元。Spyre 专注于开发针对炎症性肠病的治疗药物，特别是 SPY001，这是一种用于溃疡性结肠炎和克罗恩病的单克隆抗体</p>

<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received a consensus rating of &#34;Buy&#34; from the seven brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $54.83.</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc.（纳斯达克代码：SYRE - 获取免费报告）在目前覆盖该公司的七家券商中获得了 “买入” 的共识评级，Marketbeat 报道称。七位股票研究分析师对该股票给予了买入推荐。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 54.83 美元。</p>
</div><p>Get <strong>Spyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
</div><p>Several brokerages have recently weighed in on SYRE. Robert W. Baird upped their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, November 13th. Guggenheim raised their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 25th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th.</p>
<div class="lb-trans"><p>几家券商最近对 SYRE 进行了评估。罗伯特·W·贝尔德在 11 月 13 日的研究报告中将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并给予该公司 “跑赢大盘” 的评级。古根海姆在 10 月 25 日的研究报告中将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 1 月 13 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Spyre Therapeutics 的股票设定了 65.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Report on SYRE</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 SYRE 的最新报告</strong></p>
</div><h2>Institutional Investors Weigh In On Spyre Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Spyre Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of SYRE. Huntington National Bank bought a new position in Spyre Therapeutics in the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Spyre Therapeutics in the fourth quarter worth about $46,000. Quest Partners LLC increased its stake in Spyre Therapeutics by 271.2% during the 3rd quarter. Quest Partners LLC now owns 5,654 shares of the company's stock valued at $166,000 after buying an additional 4,131 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Spyre Therapeutics during the 4th quarter worth about $182,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Spyre Therapeutics in the 3rd quarter worth approximately $246,000. Institutional investors own 80.39% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 SYRE 的持股。亨廷顿国家银行在第四季度购买了 Spyre Therapeutics 的新头寸，价值约 34,000 美元。未来资产全球投资有限公司在第四季度收购了 Spyre Therapeutics 的新股份，价值约 46,000 美元。Quest Partners LLC 在第三季度将其在 Spyre Therapeutics 的股份增加了 271.2%。Quest Partners LLC 现在拥有 5,654 股该公司的股票，价值 166,000 美元，在此期间又购买了 4,131 股。KLP Kapitalforvaltning AS 在第四季度购买了 Spyre Therapeutics 的新股份，价值约 182,000 美元。最后，Intech Investment Management LLC 在第三季度收购了 Spyre Therapeutics 的新股份，价值约 246,000 美元。机构投资者持有该公司 80.39% 的股票。</p>
</div><h2>Spyre Therapeutics Trading Up 1.1 %</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 股价上涨 1.1%</h2>
</div><p>Shares of SYRE stock opened at $22.92 on Monday. Spyre Therapeutics has a 52 week low of $20.07 and a 52 week high of $47.97. The company has a market cap of $1.18 billion, a PE ratio of -3.07 and a beta of 2.85. The company's fifty day simple moving average is $23.11 and its 200-day simple moving average is $27.13.</p>
<div class="lb-trans"><p>SYRE 股票周一开盘价为 22.92 美元。Spyre Therapeutics 的 52 周低点为 20.07 美元，52 周高点为 47.97 美元。该公司的市值为 11.8 亿美元，市盈率为-3.07，贝塔值为 2.85。该公司的 50 日简单移动平均线为 23.11 美元，200 日简单移动平均线为 27.13 美元。</p>
</div><h2>About Spyre Therapeutics</h2>
<div class="lb-trans"><h2>关于 Spyre Therapeutics</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc.是一家处于临床前阶段的生物技术公司，专注于为患有炎症性肠病（IBD）的患者开发治疗药物。它开发的 SPY001 是一种人源单克隆免疫球蛋白 G1 抗体，旨在选择性地结合 a4ß7 整合素，正在开发用于治疗 IBD（溃疡性结肠炎和克罗恩病）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Spyre Therapeutics</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Symbotic Shares Down 37%—Is It Time for Bravery or Caution?</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>High-Yield Healthcare: 3 Stocks With Strong Dividends</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Beyond the Bargain Bin: 3 Stocks Leading Discount Retail</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Spyre Therapeutics</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>Symbotic 股价下跌 37%——是时候勇敢还是谨慎？</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>高收益医疗：3 只股息强劲的股票</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>超越折扣区：3 只领先的折扣零售股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SYRE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Where Should You Invest $1,000 Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元吗？</h2>
</div><p>Before you make your next trade, you'll want to hear this.</p>
<div class="lb-trans"><p>在你进行下一笔交易之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
</div><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p>
<div class="lb-trans"><p>我们的团队已确定五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而且没有任何大牌股票在名单上。</p>
</div><p>They believe these five stocks are the five best companies for investors to buy now...</p>
<div class="lb-trans"><p>他们认为这五只股票是投资者现在购买的五家最佳公司……</p>
</div><p>See The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div><h2>Should You Invest $1,000 in Spyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Spyre Therapeutics 吗？</h2>
</div><p>Before you consider Spyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Spyre Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Spyre Therapeutics 并不在名单上。</p>
</div><p>While Spyre Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyre Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Spyre Therapeutics, Inc. (NASDAQ:SYRE) 被分析师一致推荐为 “买入” 评级